Premium
SAFETY AND PRELIMINARY EFFICACY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA RECEIVING LISOCABTAGENE MARALEUCEL IN TRANSCEND NHL 001
Author(s) -
Wang M.,
Gordon L.I.,
Palomba M.L.,
Abramson J.S.,
Andreadis C.,
Ghosh N.,
Lunning M.,
Maloney D.,
Farazi T.,
Garcia J.,
Xie B.,
Newhall K.,
Dehner C.,
Siddiqi T.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.111_2630
Subject(s) - mantle cell lymphoma , medicine , neutropenia , fludarabine , discontinuation , ibrutinib , gastroenterology , adverse effect , febrile neutropenia , carboplatin , salvage therapy , chemotherapy , progressive disease , lymphoma , oncology , surgery , leukemia , cyclophosphamide , chronic lymphocytic leukemia , cisplatin
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom